Prostate cancer progression and surrounding microenvironment

International Journal of Biological Markers

Volumn 21, Issue 2, 2006, Pages 88-95

  Alberti, Contardo ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b NONE   (Italy)

Author keywords

Disease progression; Prostate; Prostate cancer; Stromal epithelial interaction

Indexed keywords

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CANCER MODEL; CELL INTERACTION; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; METASTASIS; MICROENVIRONMENT; MOLECULAR MECHANICS; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; STEM CELL; STROMA;

EID: 33747076326     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4500     Document Type: Article

References (96)

1. Barret JM, Mangold KA, Jilling T, Kaul KL. Bidirectional interactions of prostate cancer cells and bone marrow endothelial cells in 3-D culture. The Prostate 2005; 64: 75-82.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-70.
3. Massague J. How cells read IGF-? signals. Nat Rev Mol Cell Biol 2000; 1: 169-78.
4. Huang S, Ingber DE. The structural and mechanical complexity of cell-growth control. Nat Cell Biol 1999; 1: E131-8.
5. Yamada KM, Pankov R, Cukierman E. Dimension and dynamics in integrin function. Braz J Med Biol Res 2003: 36: 959-66.
6. Carraway KL, Carraway CA. Signaling, mitogenesis and the cytoskeleton: where the action is. Bioessays 1995; 17: 171-5.
7. Lenart P, Bacher CP, Daigle N, et al. A contractile nuclear actin network drives chromosome congression in oocytes. Nature 2005; 436: 812-8.
8. Bhandari MS, Hussain M. Epothilones and the next generation of phase III trials for prostate cancer. BJU Int 2005; 96: 296-302.
9. Zhan M, Zhao H, Han ZC. Signalling mechanisms of anoikis. Histol Histopathol 2004; 19: 973-83.
10. Griffiths G, Klumperman J. Membranes and organelles. Curr Opin Cell Biol 2004; 16: 341-2.
11. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping in extracellular messages. Curr Opin Cell Biol 2004; 16: 415-21.
12. Wang R, Xu J, Juliette L, et al. Three-dimensional co-culture models to study prostate cancer growth, progression and metastasis to bone. Semin Cancer Biol 2005; 15: 353-64.
13. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001; 294: 1661-3.
14. Selli C, Papini S, Rosellini A, De Matteis A, Revoltella R. Three dimensional organ culture of human prostatic cancer and benign tissue. Eur Urol 2005; 4 (Suppl 3): P5-78, 22.
15. Bistolfi F. BCS: the bioconductive connectional system. In: Bistolfi F. Biostructures and radiation: order disorder. Torino: Minerva Medica, 1991; 53-60.
16. Del Giudice E, Fleischmann M, Preparata G, Talpo G. On the "unreasonable" effects of ELF magnetic fields upon a system of ions. Bioelectromagnetics 2002; 23: 522-30.
17. Scherenzel J, Serrander L, Banfi B. Electron currents generated by the human phagocyte NADPH-oxidase. Nature 1998; 392: 734-7.
18. Cavelier G. Theory of malignant cell transformation by superoxide fate coupled with cytoskeletal electron-transport and electron-transfer. Med Hypotheses 2000; 54: 95-8.
19. Fuh KC, Meneshian A, Patel CB, Takiar V, Bulkey GB. Signal transduction by ROS: alternative paradigms for signaling specificity. Surgery 2002; 131: 601-12.
20. Ravid T, Sweeney C, Gee P, Carraway KL 3rd, Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. J Biol Chem 2002; 277: 31214-9.
21. Kim DY, Yoo TG, Park CH, Kim JW, Yang EK. Alterations in calcium-activated potassium channel expression in human prostate-cancer. Eur Urol 2005; 4 (Suppl): P42-721, 183.
22. Gerald WL. Genoma-wide gene expression analysis of prostate carcinoma. Semin Oncol 2003; 30: 635-48.
23. Trojan L, Steidler A, Haak M, et al. Identification of metastasis-associated genes in prostatic cancer by genetic profiling of human prostate cell lines. Eur Urol 2005; 4 (Suppl): P5-80, 22.
24. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003; 97: 772-8.
25. Paget S. The distribution of secondary growths in cancer of the breast. Cancer 1889; 1: 571-3.
26. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51: 3753-62.
27. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insight into prostatic cancer progression: the missing link of tumor microenvironment. J Urol 2005; 173: 10-20.
28. Kyker KD, Culkin DJ, Hurst RE. A model for 3-D growth of bladder cancer to investigate cell-matrix interactions. Urol Oncol 2003; 21: 255-61.
29. Horinage M, Okita H, Nakashima J, Kanao K, Sakamoto M, Murai M. Clinical and pathologic significance of activation of STAT-3 in prostate cancer. Urology 2005; 66: 671-5.
30. Shariat SF, Menessez-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of TGF-? and its receptors. Urology 2004; 63:1191-7.
31. van der Poel HG. Mammalian target of rapamycin and P13K pathway inhibition enhances growth inhibition of TGF-?1 in prostate cancer cells. J Urol 2004; 172: 1333-7.
32. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanism of metastasis. Cancer 1997; 80 (Suppl): 1529-31.
33. Singh H, Dang TG, Ayala GE, Rowley DR. Transforming growth factor-?1 induced myofibroblasts regulate LNCaP cell death. J Urol 2004; 172: 2421-5.
34. Hill R, Song Y, Cardiff RD, Dan Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-11.
35. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, Chung LW. Can cancer cells transform normal host cells into malignant cells? Br J Cancer 1997; 76: 1134-40.
36. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QZ, Li B. Androgen stimulates MM2 expression in human prostate cancer. Endocrinology 2003; 144: 1656-63.
37. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
38. Van der Poel H, Bindels E, Weijs L. Transforming growth factor-?1 and androgen signaling are mutually inhibitory in a prostate cancer cell line. Eur Urol 2005; 4 (Suppl): P5-84, 23.
39. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175: 27-34.
40. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H, Saiki I. Effect of HGF on invasion of prostate cancer cell lines. Oncol Rep 2003; 10: 1001-6.
41. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses neuroendocrine transdifferentiation process in prostate cancer cells. Molec Endocrinol 2003; 17: 1726-37.
42. Harris AL. Hypoxia, a key regulator factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
43. Thiery JP. Epithelial-mesenchymal transition in tumor progression. Nat Rev Cancer 2002; 2: 442-8.
44. Ingber DE. Cancer as a disease of epithelial-mesencymal interactions and extracellular matrix interactions and extracellular matrix regulation. Differentiation 2000; 70: 547-53.
45. Cooper CR, Chay CH, Gendernalick JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003; 97 (Suppl 3): 739-47.
46. Tanaka M, Kogawa Z, Nishihori Y. Suppression of intracellular Cu-Zn SOD results in enhanced motility and metastasis in sarcoma cells. Int J Cancer 1997; 73: 187-92.
47. Farrah K, Werner E, Tremble P, Symons M, Werb Z. Role of Rac1 and ROS in collagenase-1 expression induced by cell shape changes. Science 1998; 280: 898-902.
48. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 32: 246-61.
49. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis model. Cancer 2000; 88 (Suppl 12): 2995-3001.
50. Cher M. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001; 11: 483-8.
51. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCarley LK. Use of stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7.
52. Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki T, Yamanaka H. Increased expression of BMP-7 in bone metastatic prostate cancer. Prostate 2003; 54: 268-74.
53. Jacob K, Webber M, Benayahu D, Kleinman AK. Osteonectin promotes prostate cancer migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453-7.
54. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metast Rev 1992; 11: 353-75.
55. Kierszenbaum AL, Rivkin E, Chang PL. Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells. Prostate 2000; 43: 175-83.
56. Lehr JE, Pienta KT. Preferential adhesion of prostate cancer cells to human bone marrow endothelial cell line. J Natl Cancer Inst 1998; 90: 118-23.
57. De Palma M, Venneri MA, Galli R, et al. Tie identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-26.
58. Boguslawski G, Hale LV, Yu XP, et al. Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J Biol Chem 2000; 275: 999-1006.
59. Brown JM, Corey E, Lee ZD. Osteoprotegerin and RANKL expression in prostate cancer. Urology 2001; 57: 611-7.
60. Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells of the early response genes for jun and myc by the ATF of urokinase. J Cell Physiol 1997; 172: 137-45.
61. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997; 80: 1581-7.
62. Guise TA, Yin JJ, Mohammad KS. Role of E-1 in osteoblastic bone metastases. Cancer 2003; 97 (Suppl): 779-84.
63. Hamdy FC. Endothelin and skeletal metastases in hormone-refractory prostate cancer. Eur Urol 2003; 2 (Suppl): 15-9.
64. Nelson JB, Hedican SP, George DJ, et al. Identification of ET-1 in the pathophysiology of metastatic cancer of the prostate. Nat Med 1995; 1: 944-9.
65. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001; 49: 267-77.
66. Lee HL, Cooper CR, Pienta KJ. The effect of growth factors and cytokines on the growth of androgen sensitive and insensitive human prostate cancer cells in vitro. Proc Am Assoc Cancer Res 2002; 43: A187.
67. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88 (Suppl 12); 2892-8.
68. Guise TA. Parathyroid-hormone related protein and bone metastases. Cancer 1997; 80 (Suppl 8): 1572-80.
69. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80 (Suppl 8): 1546-56.
70. Iwamura M, di Sant'Agnese PA, Wu G, Bennin CM, Cockett ATK, Deftos LJ. Immunochemical localization of PTH-rP in human prostate cancer. Cancer Res 1993; 53: 1724-6.
71. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves PTH-rP in the PTH-like domain: inactivation of PTH-rP stimulated cAMP accumulation in mouse osteoblasts. J Uroi 1996; 156: 526-30.
72. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997; 80 (Suppl 8): 1564-71.
73. Key LL Jr, Wolf WC, Gundberg CM, Ries WL. Superoxide and bone resorption. Bone 1994; 15: 431-6.
74. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003; 30: 649-58.
75. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003; 30: 659-66.
76. Aalamian M, Tourkova I, Chatta C, et al. Inhibition of dendropoiesis by tumor-derived and purified PSA. J Urol 2003; 170: 2026-30.
77. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-35.
78. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stem PL. Loss of HLA class I expression in prostate cancer. Implications for immunotherapy. Urology 1995; 46: 681-7.
79. Totterman Th, Loskog A, Essand M. The immunotherapy of prostate and bladder cancer. BJU Int 2005; 96: 728-35.
80. Roden AC, Moser MT, Tri SD, et al. Augmentation of T-cell levels induced by androgen deprivation. J Immunology 2004; 173: 6098-105.
81. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate cancer-restricted antigen. Cancer Cell 2005; 7: 239-50.
82. Akakura K, Suzuki H, Ueda T, et al. Possible mechanism of dexamethasone therapy for prostate cancer. Prostate 2003; 56: 106-9.
83. Pardal R, Clarke MF, Morrison GJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
84. Molofsky AV, Pardal R, Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 2004; 16: 700-7.
85. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 842-50.
86. Hatfield SD, Shcherbata HR, Fisher KA, Nakahara K, Carthew RW, Ruotola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005; 435: 974-8.
87. Maitland NJ, Collins A. A tumor stem cell hypothesis for the origin of prostate cancer. BJU Int 2005; 96: 1219-23.
88. Jalcut MW, Reiter RE. Role of PSCA in prostate cancer research. Curr Opin Urol 2002; 12: 401-6.
89. Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. J Urol 2005; 174: 820-6.
90. Hyytinen ER, Thalmann GN, Zhau HE, et al. Genetic changes associated with acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997; 75: 190-5.
91. Ramaswamy S, Ross KN, Lander ES, Golup TR. A molecular signature of metastasis in primary solid tumours. Nat Genet 2003; 33: 49-53.
92. Chung LW. The roles of myofibroblasts in prostate carcinogenesis. J Urol 2004; 172: 2125-6.
93. Chung LW, Hsieh CL, Law A, Sung SY, Gardner TA, Egawa M. New targets for therapy in prostate cancer: modulation of stromal ephitelial interactions. Urology 2003; 62: 447-54.
94. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4: 657-61.
95. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-55.
96. Xie S, Lin HK, Ni J, et al. Regulation by androgen signaling in prostate cancer cells. Prostate 2004; 60: 61-7.